Life Technologies, Inc. (“LTI”) appeals the judgment of the United States District Court for the District of Maryland, entered after a bench trial, in which the court held that LTI’s U.S. Patents Nos. 5,244,797 (“the ’797 patent”) and 5,668,005 (“the ’005 patent”) were unenforceable on the ground of inequitable conduct. Because the court premised this determination on clearly erroneous findings of fact, we reverse and remand.
BACKGROUND
Reverse transcriptase (“RT”) is a naturally occurring enzyme that exhibits DNA polymerase activity. DNA polymerase activity enables the RT enzyme to utilize a messenger RNA (“mRNA”) molecule as a template to synthesize a complementary strand of DNA (“cDNA”). This reaction results in a DNA/RNA hybrid molecule. In addition to DNA polymerase activity, naturally occurring RT, known as “wild-type” RT, also exhibits RNase H activity. RNase H activity degrades the original mRNA template as the cDNA molecule is made. RNase H activity is undesirable because this degradation of the mRNA template negatively affects the ability and efficiency of the RT to make cDNA.
Beginning in the early 1980’s, the inventors of the ’797 and ’005 patents, Drs. Michael Kotewicz and Gary Gerard, sought to develop a genetically engineered RT enzyme that exhibited DNA polymerase activity but did not substantially exhibit RNase H activity. Kotewicz and Gerard faced several difficulties in developing this enzyme. First, it was unknown at the time where on the RT molecule the DNA polymerase and RNase H activities resided. Further, it was unknown whether the RNase H activity could be selectively removed to produce an improved mutant RT enzyme that retained DNA polymerase activity. The inventors spent several years unsuccessfully attempting to locate and delete the RNase H activity from the RT molecule.
The breakthrough for the inventors came in 1986 with the publication of M.S. Johnson et al., Computer Analysis of Re-troviral Pol Genes: Assignment of Enzymatic Functions to Specific Sequences and Homologies with Nonviral Enzymes, 83 Proceedings of the Nat’l. Acad, of Sci. 7648 (1986) (“the Johnson article”). The Johnson article reported comparisons made between amino sequences of certain RT molecules and the sequence of the ri-bonuclease enzyme from E. coli, which exhibits RNase H activity but not DNA polymerase activity. The findings of Johnson suggested to the inventors that the RNase H activity of the RT enzyme resided at the carboxyl terminal end of the molecule. The inventors, however, were skeptical of Johnson’s results because the literature existing at the time suggested that the location of the RNase H activity was at the front end of the RT molecule. Additionally, the Johnson article was suspect because it utilized computer comparisons of amino acid sequences, rather than experimental data. Such computer comparisons were fairly new in the art at the time. Thus, in order to “exclude the possibility” that Johnson was correct, Kotewicz and Gerard decided to conduct experiments at the carboxyl terminal end of the RT enzyme. Contrary to expectations, these experiments were successful and, by December 1986, the inventors had created a mutant RT enzyme that lacked RNase H activity but retained DNA polymerase activity.
A few months after confirming their discovery, Kotewicz and Gerard learned that another researcher, Dr. Stephen Goff, was working to develop an engineered RT en
In January 1988, Kotewiez and Gerard filed the parent application from which the ’797 and ’005 patents ultimately issued. In general, the application claimed an engineered RT enzyme that exhibited DNA polymerase activity but did not exhibit substantial RNase H activity. As part of the duty of disclosure under 37 C.F.R. § 1.56, the inventors disclosed to the Patent and Trademark Office (“PTO”) numerous prior art references, including the Johnson article. However, the inventors did not reveal their knowledge of Goffs work because their patent attorney indicated that such limited and incomplete information would not be material.
During the prosecution leading to the ’797 patent, the Johnson article took on particular importance for the Examiner. Several times, the Examiner rejected the inventors’ claims as obvious over Johnson, often in combination with other prior art that described the RT gene sequence. According to the Examiner, because Johnson taught that the RNase H activity was located at the carboxyl terminal end, and because there was a strong motivation in the art to eliminate such activity, the claimed invention would have been obvious. In response to these rejections, the inventors argued that, at the time of the invention, there would have been no reasonable expectation that the application of Johnson’s results would successfully lead to the deletion of RNase H activity. This was because the teachings of Johnson were contrary to teachings in the prior art which suggested that “something more was necessary” than a deletion at the car-boxyl terminal end to eliminate RNase H activity. Thus, the inventors contended that the claimed invention would not have been obvious over Johnson. The Examiner was persuaded by these arguments, and the ’797 patent issued on September 19, 1993. At no time during this prosecution did the inventors reveal to the Examiner that the Johnson article played a key role in their development of the claimed invention.
Shortly after the issuance of the ’797 patent, the inventors filed the continuation application that eventually resulted in the issuance of the ’005 patent. During the prosecution of this application, the inventors revealed their knowledge of Goffs work. The Examiner allowed the application to issue over the newly revealed information regarding Goff, stating that the new information had “no bearing on ... the instant application.”
In December 1996, LTI sued Clontech Laboratories, Inc. (“Clontech”) for infringement of the ’797 and ’005 patents. In response, Clontech asserted various affirmative defenses, including an allegation that the patents should be held unenforceable due to inequitable conduct. A bench trial on the inequitable conduct issue ensued. After the trial, the court found that the inventors withheld material information regarding the motivations that they derived from the Johnson article and then-reliance on it in reaching their invention. The court also found that the inventors made affirmative material misrepresentations during prosecution regarding the
DISCUSSION
Applicants for patents, including their legal representatives, have the duty to prosecute patent applications in the PTO with candor, good faith, and honesty.
See Molins PLC v. Textron, Inc.,
Inequitable conduct can consist of affirmative misrepresentations of material fact, submission of false material information, or the failure to disclose known material information during the prosecution of a patent, coupled with the intent to deceive the PTO.
See Molins, 48
F.3d at 1178,
Because the determination of inequitable conduct is ultimately committed to the discretion of the district court, we review its determination for abuse of discretion.
See Kingsdown,
The district court determined that the inventors committed inequitable conduct based on three actions during the prosecution of the ’797 patent — withholding information regarding their “reliance” on the Johnson article, making material misrepresentations regarding the Johnson article, and withholding information regarding Goffs work. We will address each of these actions in turn.
1. Withholding Information Regarding the Johnson Article
As described above, the Johnson article was extremely influential in leading
Information is material when there is a substantial likelihood that a reasonable Examiner would have considered the information important in deciding whether to allow the application to issue as a patent.
See Molins,
Inventors, as a class, according to the concepts underlying the Constitution and the statutes that have created the patent system, possess something — call it what you will — which sets them apart from the workers of ordinary skill, and one should not go about determining obviousness under § 103 by inquiring into what patentees ... would have known or would likely have done, faced with the revelations of references.
Id. Furthermore, the path that leads an inventor to the invention is expressly made irrelevant to patentability by statute. See 35 U.S.C. § 103(a) (“Patentability shall not be negatived by the manner in which the invention was made.”). Thus, the inventors’ rebanee on the Johnson article and the motivations that they derived from it have no bearing on the issue of patentability. It does not matter whether the inventors reached their invention after an exhaustive study of the prior art, or developed their RT enzymes in complete isolation. The only inquiry is whether the teachings of the Johnson article, in combination with other relevant prior art, would have rendered the claimed invention obvious to one of ordinary skill in the art; this inquiry, as a matter of law, is independent of the motivations that led the inventors to the claimed invention. Therefore, the district court clearly erred by finding that the inventors’ reliance on Johnson was material.
2. Material Misrepresentations Regarding the Johnson Article
The district court also found that the inventors made affirmative misrepresentations regarding the Johnson article. During the prosecution of the ’797 patent, the inventors were faced with rejections based on Johnson, which taught the location of the RNase H activity, in combination with other prior art references that described the RT enzyme itself. In response to these rejections, the inventors argued that this combination did not render the claimed invention obvious because at the time the invention was made, one of ordinary skill in the art would have thought that “something more was necessary” than a deletion at the carboxyl terminal end to eliminate RNase H activity. Thus, they argued, there would have been no reasonable expectation of success in applying Johnson’s teachings. The court
It is axiomatic that a claimed invention is not obvious solely because it is composed of elements that are all individually found in the prior art.
See, e.g., In re Rouffet,
First, in making the argument, the inventors merely advocated a particular interpretation of the teachings of the Johnson article and the level of skill in the art, which the Examiner was free to accept or reject. This argument did not contain any factual assertions that could give rise to a finding of misrepresentation.
See, e.g., Akzo N.V. v. United States Int’l Trade Comm’n,
3. Withholding Knowledge of Goffs Work
Finally, the district court determined that the inventors had withheld material information regarding Goffs work. Specifically, the court found that the inventors should have revealed that Goff claimed to have developed “oligonucleotide insertion mutations that reducefd] RNase H in cloned [RT],” and had presented these results at a conference during the summer of 1987. The court clearly erred in finding that this information was material.
As described above, information is material when there is a substantial likelihood that a reasonable Examiner would have considered the information important in
To establish prior inventorship, one must show either a prior reduction to practice of the invention or a prior conception followed by reasonable diligence in reducing the invention to practice.
See Eaton v. Evans,
Moreover, the inventors did not obtain any material information regarding Goffs work based on his presentation at Stanford. The inventors neither attended this presentation, nor were provided with an abstract of the presentation. They had heard from colleagues that Goff presented results similar to theirs, but the record does not show that the inventors learned any additional details regarding Goffs work. Thus, the inventors could not have revealed anything to the Examiner regarding this presentation beyond conjecture and a vague report that “similar results” were presented. Such incomplete information would be singularly unhelpful to the Examiner in determining whether the invention was patentable, and consequently, would not be material.
CONCLUSION
The district court clearly erred in finding that the inventors withheld material information and made affirmative misrepresentations during the prosecution of the patents at issue. Therefore, the court’s determination that the inventors engaged in inequitable conduct is reversed, and this case is remanded for further proceedings.
COSTS
Each party shall bear its own costs.
REVERSED AND REMANDED.
